electroCore (ECOR) Stock: Buy, Sell, or Hold?
ECOR - electroCore, Inc. Common Stock
$10.18
0.04 (0.39%)
â˛
5d:
-7.71%
30d:
+10.53%
90d:
+28.7%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 04, 2026
29d
Get Alerted When ECOR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: ECOR is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: ECOR is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: ECOR is currently trading at $10.18, which is considered fair relative to its 30-day fair value range of $9.31 to $11.26.
Technical Outlook: Technically, ECOR is in a uptrend. The price is currently testing key support at $9.90. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ECOR scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $19.17 (+89.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ECOR is in a uptrend. The price is currently testing key support at $9.90. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ECOR scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $19.17 (+89.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$9.31 -
$11.26
Company Quality Score
36/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
50.0%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 89.1% below Wall St target ($19.17)
- WARNING: Composite score 36/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$9.31 -
$11.26
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$9.90
Resistance Level
$12.70
Current Trend
Uptrend
Technical data as of
Oct 5, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-16.29
Wall Street Target
$19.17
(+89.1%)
Revenue Growth (YoY)
28.0%
Profit Margin
-40.0%
Share & Embed Analysis
Last updated: October 05, 2026 3:06 PM ET
Data refreshes hourly during market hours. Next update: 4:06 PM
Data refreshes hourly during market hours. Next update: 4:06 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ECOR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Daniel S Goldberger
SELL
16072 shares
2026-04-10
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SYK
Stryker Corporation |
STRONG BUY
28 analysts |
$368 | 63 BUY |
|
EW
Edwards Lifesciences Corp |
STRONG BUY
29 analysts |
$101 | 60 BUY |
|
DXCM
DexCom Inc |
STRONG BUY
28 analysts |
$95 | 46 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$121 | 55 HOLD |
|
MDT
Medtronic PLC |
BUY
28 analysts |
$105 | 63 BUY |
